Formulation development and evaluation of pulsatile drug delivery system of zafirlukast tablets
International Journal of Development Research
Formulation development and evaluation of pulsatile drug delivery system of zafirlukast tablets
Received 11th February, 2023; Received in revised form 19th March, 2023; Accepted 21st March, 2023; Published online 30th April, 2023
Copyright©2023, P. SS Prasanna Kumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The objective of the study to formulate and evaluate ofpulsatile drug delivery containing Zafirlukastfor the treatment of asthama which is used to deliver the drug atspecific time as per pathophysiological need of the disease and improvementof therapeutic efficacy and patient compliance. Zafirlukastin the core tablet was formulated with different concentration of superdisintegrants and microcrystalline cellulose, an outer shell tablet which is formulated with different weight ratios of polymers HPMC K100M, Eudragit RSPO and Xanthan gum.The effects of the formulation of core tablet and outer shell of press coated tablets; on drug release and the lag time were investigated.The formulation was optimized based on acceptable tablet properties and in vitro drug release.The release profile of press coated tablet exhibited a lag time dependent upon the amount of polymers in compression coating. The optimized batch F3 gave a lag time of 2 h and drug release of 99.31% of Zafirlukastrespectively. Based on the results programmable pulsatilerelease has been achieved by formulation F3 which meet the demand ofChrono therapeutic objective of asthama.
